Ketamine (IV / Esketamine) and Neuropathic Pain: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Ketamine (IV / Esketamine) and Neuropathic Pain: Latest Research 2026

This page summarizes the current state of scientific research on Ketamine (IV / Esketamine) in the context of Neuropathic Pain as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your neurologist or pain specialist for personalized guidance.

Compound Overview

Ketamine (IV / Esketamine) (NMDA Antagonist / Anesthetic) — FDA-approved as anesthetic; esketamine (Spravato) approved for treatment-resistant depression

Mechanism of action: NMDA receptor antagonism; rapid antidepressant via AMPA activation; opioid receptor modulation; BDNF release

Current evidence level: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies

2026 Research Landscape

Research has directly examined Ketamine (IV / Esketamine) in Neuropathic Pain, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Ketamine (IV / Esketamine) affects the biological pathways involved in Neuropathic Pain progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Ketamine (IV / Esketamine) in Neuropathic Pain patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Ketamine (IV / Esketamine)[tiab]) AND (Neuropathic Pain[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Ketamine (IV / Esketamine) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Ketamine (IV / Esketamine) + Neuropathic Pain research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Neuropathic Pain patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Ketamine (IV / Esketamine) for Neuropathic Pain?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Ketamine (IV / Esketamine) Neuropathic Pain' filtered to the last 2 years. The current evidence level is: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies.

Are there any 2025-2026 clinical trials for Ketamine (IV / Esketamine) in Neuropathic Pain?

Check ClinicalTrials.gov with 'Ketamine (IV / Esketamine)' as intervention and 'Neuropathic Pain' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your neurologist or pain specialist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Ketamine (IV / Esketamine) in Neuropathic Pain changed recently?

The field evolves rapidly. The current evidence classification is: Strong data for treatment-resistant depression; Phase II for neuropathic pain; cancer anxiety studies. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.